Shaji Kumar - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Shaji Kumar's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Shaji Kumar
Verified
Editor, Blood Cancer Journal
Beats
theme parks, recoverySobriety, wellness trauma, faith mental health
Culture
Content
Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma - Leukemia
By Moritz Binder, Joselle M. Cook, Morie A Gertz, Prashant Kapoor, Taxiarchis Kourelis, Shaji Kumar Verified, Mustaqeem Siddiqui, Yi Lin| Nature Verified To the EditorTherapy for relapsed and refractory multiple myeloma (RRMM) has been revolutionized with the availability of chimeric antigen receptor T cell therapy (CAR-T) [1,2,3,4,5,6]. Currently idecabtagene vicleucel (Ide-Cel) [2, 3] and ciltacabtagene autoleucel (Cilta-cel) [4, 5], are approved by the Food and Drug Administration (FDA). Both products result in rapid and deep responses and improve overall survival in patients with RRMM.
Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702 - Leukemia
By Rahul Banerjee, Amber Fritz, Ciara L Freeman, Heather Landau, Shaji Kumar Verified, Dan T. Vogl, Philip L McCarthy| Nature Verified International Myeloma Working Group (IMWG) response criteria for multiple myeloma (MM) currently involve a combination of blood-based, urine-based, and marrow-based assessments [1]. Unlike blood-based assays which can be obtained from a single venipuncture, urine testing in MM requires that every urinary void over a 24-h period be collected.
Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma - Leukemia
By Moritz Binder, Joselle M. Cook, Morie A Gertz, Prashant Kapoor, Taxiarchis Kourelis, Shaji Kumar Verified, Mustaqeem Siddiqui, Yi Lin| Nature Verified To the EditorTherapy for relapsed and refractory multiple myeloma (RRMM) has been revolutionized with the availability of chimeric antigen receptor T cell therapy (CAR-T) [1,2,3,4,5,6]. Currently idecabtagene vicleucel (Ide-Cel) [2, 3] and ciltacabtagene autoleucel (Cilta-cel) [4, 5], are approved by the Food and Drug Administration (FDA). Both products result in rapid and deep responses and improve overall survival in patients with RRMM.
Company Info
Blood Cancer Journal
The Office for Education Diversity, Equity & Inclusion (OEDEI) at Mayo Clinic College of Medicine and Science is dedicated to enhancing diversity, equity, and inclusion within the institution. It operates as part of Mayo Clinic's commitment to fostering a welcoming environment across its educational programs. OEDEI offers pathway programs aimed at addressing disparities in medical education and patient care, specifically supporting underrepresented groups in medicine. The office plays a key role in creating an inclusive learning environment where all learners feel respected and supported. Additionally, it implements initiatives to recruit and retain a diverse community of learners, staff, and faculty, aligning with Mayo Clinic's mission to combat racism and discrimination.
Rochester, Minnesota, United States
507-255-7949